Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMP: Switching to Aripiprazole for Metabolic Risk in Schizophrenia
NCT00423878Phase 4Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jan 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole in schizophrenia, schizoaffective disorder, sponsored by National Institute of Mental Health. Started Jan 2007; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00423878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423878.